Tuberculosis, drug resistance, and the history of modern medicine

New England Journal of Medicine

Volumn 367, Issue 10, 2012, Pages 931-936

  Keshavjee, Salmaan ^a,b,c   Farmer, Paul E ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PARTNERS IN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC ANALYSIS; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

EID: 84865677110     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1205429     Document Type: Review

References (50)

1. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995;333:229-33.
2. Kim JY, Mukherjee J, Rich ML, Mate K, Bayona J, Becerra MC. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis (Edinb) 2003;83:59-65.
3. Keshavjee S, Farmer PE. Picking up the pace - scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010;363:1781-4.
4. Dheda K, Shean K, Badri M. Extensively drug-resistant tuberculosis. N Engl J Med 2008;359:2390.
5. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81.
6. Daniel TM. Captain of death: the story of tuberculosis. Rochester, NY: University of Rochester Press, 1997:80-1.
7. Holmberg SD. The rise of tuberculosis in America before 1820. Am Rev Respir Dis 1990;142:1228-32.
8. Koch R. The aetiology of tuberculosis. New York: National Tuberculosis Association, 1932:47.
9. Hinshaw HC, Feldman WH, Pfuetze KH. Treatment of tuberculosis with streptomycin: a summary of observations on one hundred cases. J Am Med Assoc 1946;132:778-82.
10. Jellinek K. Streptomycin in the treatment of extrapulmonary tuberculosis: early results. N Engl J Med 1949;240:680-3.
11. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82.
12. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948;2:1009-15.
13. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid: a Medical Research Council investigation. Br Med J 1950;2:1073-85.
14. Selikoff IJ, Robitzek EH, Ornstein GG. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. J Am Med Assoc 1952;150:973-80.
15. Daniel TM. Rifampin - a major new chemotherapeutic agent for the treatment of tuberculosis. N Engl J Med 1969;280:615-6.
16. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections. N Engl J Med 1970;283:616-21.
17. Cegielski JP. Extensively drug-resistant tuberculosis: "there must be some kind of way out of here." Clin Infect Dis 2010;50:Suppl 3:S195-S200.
18. Manten A, Van Wijngaarden LJ. Development of drug resistance to rifampicin. Chemotherapy 1969;14:93-100.
19. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:Suppl 2:S231-S279.
20. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: a national survey, 1955-56. Tubercle 1957;38:71-84.
21. Steiner M, Chaves AD, Lyons HA, Steiner P, Portugaleza C. Primary drug-resistant tuberculosis: report of an outbreak. N Engl J Med 1970;283:1353-8.
22. Villarino ME, Geiter LJ, Simone PM. The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis. Public Health Rep 1992;107:616-25.
23. Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986;315:1570-5.
24. Castro KG, LoBue P. Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally. Emerg Infect Dis 2011;17:337-42.
25. Walsh JA, Warren KS. Selective primary health care: an interim strategy for disease control in developing countries. N Engl J Med 1979;301:967-74.
26. Unger JP, Killingsworth JR. Selective primary health care: a critical review of methods and results. Soc Sci Med 1986;22:1001-13.
27. Stein H. Beyond the World Bank agenda: an institutional approach to development. Chicago: University of Chicago Press, 2008.
28. Gish O. Selective primary health care: old wine in new bottles. Soc Sci Med 1982;16:1049-1054.
29. Berman PA. Selective primary health care: is efficient sufficient? Soc Sci Med 1982;16:1054-9.
30. Murray CJL. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994;72:429-45.
31. World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993.
32. Kochi A. Tuberculosis control - is DOTS the health breakthrough of the 1990s? World Health Forum 1997;18:225-32.
33. Farmer PE. Social scientists and the new tuberculosis. Soc Sci Med 1997;44:347-58.
34. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996;275:452-7.
35. McKenna MT, McCray E, Jones JL, Onorato IM, Castro KG. The fall after the rise: tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998;88:1059-63.
36. National action plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41(RR-11):5-48.
37. Fauci AS. The research path to tuberculosis control: an NIH perspective. November 5, 2008 (http://iom.edu/~/media/Files/Activity%20Files/Research/ DrugForum/Fauci.pdf).
38. WHO report on the tuberculosis epidemic, 1997. Geneva: World Health Organization, 1997.
39. Migliori GB, Espinal M, Danilova ID, Punga W, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002;6:858-64.
40. Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO retreatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999;3:451-3.
41. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000;4:108-14.
42. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
43. Suárez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002;359:1980-9.
44. Han LL, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005;9:818-21.
45. Vásquez-Campos L, Asencios-Solis L, Leo-Hurtado E, et al. Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001. Int J Tuberc Lung Dis 2004;8:465-72.
46. Tahaoǧlu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170-4.
47. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-26.
48. Gupta R, Kim JY, Espinal MA, et al. Responding to market failures in tuberculosis control. Science 2001;293:1049-51.
49. Farmer P. Infections and inequalities: the modern plagues. Berkeley: University of California Press, 1999.
50. Keshavjee S, Farmer PE. Time to put boots on the ground: making universal access to MDR-TB treatment a reality. Int J Tuberc Lung Dis 2010;14:1222-5.